Methods to facilitate the prognostic assessment of patients with status epilepticus using clinical and biological biomarkers epilepsy

Status epilepticus (SE) is a life-threatening condition characterized by prolonged epileptic seizures. As the most extreme form of epilepsy, it is the 2nd most frequent neurological emergency after stroke.

We identified a mixed clinical-biological test performed on blood samples and clinical questionnaires in order to obtain demographic data (age, history of epilepsy, etc.). This test optimizes the prognostic assessment of patients with status epilepticus (defined as a seizure lasting too long and not terminating spontaneously) in terms of mortality, functional degradation and recovery capacities. The variables used in this test allow us to identify 41% of the patients who will not survive in intensive care, and 94% of the patients who will survive.

This clinical exam represents the first scale that could be used routinely to optimize the prognostic assessment of patients with status epilepticus. This "triage" ensures better therapeutic management, while also resulting in significant potential savings. Indeed, status epilepticus is one of the main neurological emergencies, with the average hospital cost being US $ 18,834 (US) per admission.

Clinical data available – POC on patients

Patents
EP21306212.8 + PCT